Distinct antibody and memory B cell responses in SARS individuals after mRNA vaccination

Science Immunology

6,

DOI: 10.1126/sciimmunol.abi6950

Citation Report

#	Article	IF	Citations
1	Positivity of SARS-CoV-2 Antibodies among Korean Healthy Healthcare Workers 1 and 2 Weeks after Second Dose of Pfizer-BioNTech Vaccination. Journal of Korean Medical Science, 2021, 36, e158.	1.1	11
2	Neutralizing Antibodies Against SARS-CoV-2 Variants Induced by Natural Infection or Vaccination: A Systematic Review and Individual Data Meta-Analysis. SSRN Electronic Journal, 0, , .	0.4	7
6	Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science, 2021, 372, 1418-1423.	6.0	286
12	SARS-CoV-2 vaccines: anamnestic response in previously infected recipients. Cell Research, 2021, 31, 827-828.	5.7	15
14	Anti-SARS-CoV-2 Antibodies Testing in Recipients of COVID-19 Vaccination: Why, When, and How?. Diagnostics, 2021, 11, 941.	1.3	45
15	SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients. Science Immunology, 2021, 6, .	5.6	455
20	Is a single COVID-19 vaccine dose enough in convalescents ?. Human Vaccines and Immunotherapeutics, 2021, 17, 2959-2961.	1.4	10
22	Neutralizing Anti-SARS-CoV-2 Antibody Titer and Reported Adverse Effects, in a Sample of Italian Nursing Home Personnel after Two Doses of the BNT162b2 Vaccine Administered Four Weeks Apart. Vaccines, 2021, 9, 652.	2.1	27
23	Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. Science Immunology, 2021, 6, eabj1031.	5.6	223
24	Memory B Cells in Pregnancy Sensitization. Frontiers in Immunology, 2021, 12, 688987.	2.2	2
25	Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses. ACS Nano, 2021, 15, 11180-11191.	7.3	60
26	Hybrid immunity. Science, 2021, 372, 1392-1393.	6.0	218
28	Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature, 2021, 595, 426-431.	13.7	610
29	The Beauty of Simplicity: Delayed-Type Hypersensitivity Reaction to Measure Cellular Immune Responses in RNA-SARS-Cov-2 Vaccinated Individuals. Vaccines, 2021, 9, 575.	2.1	9
30	Is one vaccine dose enough if youâ€™ve had COVID? What the science says. Nature, 2021, 595, 161-162.	13.7	26
32	COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. Nature Communications, 2021, 12, 3991.	5.8	241
33	Antibody response after one and two jabs of the BNT162b2 vaccine in nursing home residents: The CONsortâ€19 study. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 271-281.	2.7	30
36	Beyond neutralization for BNT162b2 mRNA vaccination. Cell Host and Microbe, 2021, 29, 1033-1035.	5.1	3

#	Article	IF	Citations
37	Neutralizing Antibodies Titers and Side Effects in Response to BNT162b2 Vaccine in Healthcare Workers with and without Prior SARS-CoV-2 Infection. Vaccines, 2021, 9, 742.	2.1	39
38	A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and TÂcell responses. Cell Host and Microbe, 2021, 29, 1137-1150.e6.	5.1	173
39	Potency of BNT162b2 and mRNAâ€1273 vaccineâ€induced neutralizing antibodies against severe acute respiratory syndromeâ€CoVâ€2 variants of concern: A systematic review of in vitro studies. Reviews in Medical Virology, 2022, 32, e2277.	3.9	57
43	Human Coronaviruses: Counteracting the Damage by Storm. Viruses, 2021, 13, 1457.	1.5	5
46	Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine. Nature, 2021, 597, 268-273.	13.7	279
53	Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nature Reviews Immunology, 2021, 21, 475-484.	10.6	434
54	Strong antibody response after a first dose of a SARS-CoV-2 mRNA-based vaccine in kidney transplant recipients with a previous history of COVID-19. American Journal of Transplantation, 2021, 21, 3808-3810.	2.6	20
55	Neutralization of Delta variant with sera of Covishieldâ„¢ vaccinees and COVID-19-recovered vaccinated individuals. Journal of Travel Medicine, 2021, 28, .	1.4	28
56	Immunity to SARSâ€CoVâ€2 induced by infection or vaccination. Journal of Internal Medicine, 2022, 291, 32-50.	2.7	97
57	Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2. EBioMedicine, 2021, 70, 103523.	2.7	42
59	Monitoring Serum Spike Protein with Disposable Photonic Biosensors Following SARS-CoV-2 Vaccination. Sensors, 2021, 21, 5857.	2.1	32
60	Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers. Vaccines, 2021, 9, 913.	2.1	12
61	Vaccination versus infection with SARSâ€CoVâ€2: Establishment of a high avidity IgG response versus incomplete avidity maturation. Journal of Medical Virology, 2021, 93, 6765-6777.	2.5	43
62	B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19. EBioMedicine, 2021, 70, 103539.	2.7	67
63	Challenges and Scientific Prospects of the Newest Generation of mRNA-Based Vaccines against SARS-CoV-2. Life, 2021, 11, 907.	1.1	20
64	Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice. Military Medical Research, 2021, 8, 47.	1.9	88
65	Robust Antibody Responses to the BNT162b2 mRNA Vaccine Occur Within a Week After the First Dose in Previously Infected Individuals and After the Second Dose in Uninfected Individuals. Frontiers in Immunology, 2021, 12, 722766.	2.2	20
66	Human vaccines & immunotherapeutics: news. Human Vaccines and Immunotherapeutics, 2021, 17, 2354-2355.	1.4	0

#	Article	IF	Citations
70	A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants. Immunity, 2021, 54, 2159-2166.e6.	6.6	52
71	High-affinity memory B cells induced by SARS-CoV-2 infection produce more plasmablasts and atypical memory B cells than those primed by mRNA vaccines. Cell Reports, 2021, 37, 109823.	2.9	73
73	Advances in understanding the formation and fate of B-cell memory in response to immunization or infection. Oxford Open Immunology, 2021, 2, .	1.2	3
75	Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nature Medicine, 2021, 27, 1990-2001.	15.2	396
76	Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Regional Health - Europe, The, 2021, 10, 100208.	3.0	446
77	What we know and still ignore on COVIDâ€19 immune pathogenesis and a proposal based on the experience of allergic disorders. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1114-1128.	2.7	6
79	The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity. Frontiers in Immunology, 2021, 12, 737083.	2.2	18
80	SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically NaÃ¯ve and Pre-Immune Humans. Frontiers in Immunology, 2021, 12, 728021.	2.2	20
82	Shooting at a Moving Targetâ€"Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development. Vaccines, 2021, 9, 1052.	2.1	22
83	The biological and clinical significance of emerging SARS-CoV-2 variants. Nature Reviews Genetics, 2021, 22, 757-773.	7.7	778
88	Rapid induction of antigen-specific CD4+ TÂcells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. Immunity, 2021, 54, 2133-2142.e3.	6.6	367
90	Nanovaccine: an emerging strategy. Expert Review of Vaccines, 2021, 20, 1273-1290.	2.0	50
91	Neutralizing Antibodies against SARS-CoV-2, Anti-Ad5 Antibodies, and Reactogenicity in Response to Ad5-nCoV (CanSino Biologics) Vaccine in Individuals with and without Prior SARS-CoV-2. Vaccines, 2021, 9, 1047.	2.1	23
92	Serologic response to COVID-19 infection and/or vaccine in cancer patients on active treatment. ESMO Open, 2021, 6, 100283.	2.0	39
93	mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants. Immunity, 2021, 54, 2893-2907.e5.	6.6	107
94	COVID-19 Vaccination in Pregnancy and Lactation: Current Research and Gaps in Understanding. Frontiers in Cellular and Infection Microbiology, 2021, 11, 735394.	1.8	35
95	Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors. Nature Medicine, 2021, 27, 2002-2011.	15.2	167
96	Overview of the neutralizing antibody and memory B cell response kinetics in SARS-CoV-2 convalescent and/or mRNA vaccinated individuals.. Systems Biology and Physiology Reports, 2021, 1, 1-5.	0.4	2

#	Article	IF	Citations
97	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. New England Journal of Medicine, 2021, 385, 1761-1773.	13.9	1,090
98	Uninformative and unuseful: why it is necessary to actively challenge COVID-19 antibody testing postvaccination. Public Health, 2021, 199, 32-33.	1.4	2
99	Time since SARS-CoV-2 infection and humoral immune response following BNT162b2 mRNA vaccination. EBioMedicine, 2021, 72, 103589.	2.7	16
101	mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science, 2021, 374, abm0829.	6.0	609
102	Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell, 2021, 184, 5699-5714.e11.	13.5	262
103	Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clinical Microbiology and Infection, 2022, 28, 202-221.	2.8	569
105	Highly versatile antibody binding assay for the detection of SARS-CoV-2 infection and vaccination. Journal of Immunological Methods, 2021, 499, 113165.	0.6	6
106	mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status. ELife, 2021, 10, .	2.8	63
107	Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. Nature, 2021, 600, 517-522.	13.7	239
109	An affinity-enhanced, broadly neutralizing heavy chainâ€“only antibody protects against SARS-CoV-2 infection in animal models. Science Translational Medicine, 2021, 13, eabi7826.	5.8	41
110	Dynamic SARS-CoV-2-specific B-cell and T-cell responses following immunization with an inactivated COVID-19 vaccine. Clinical Microbiology and Infection, 2022, 28, 410-418.	2.8	64
111	Hallmarks of immune response in COVID-19: Exploring dysregulation and exhaustion. Seminars in Immunology, 2021, 55, 101508.	2.7	37
112	Trivalent nucleoside-modified mRNA vaccine yields durable memory B cell protection against genital herpes in preclinical models. Journal of Clinical Investigation, 2021, 131, .	3.9	17
113	Clinical and immunological characteristics in COVID-19 convalescent patients. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 2669-2676.	1.3	1
115	Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?. Lancet Respiratory Medicine,the, 2021, 9, 1450-1466.	5.2	110
117	Generation and persistence of S1ÂIgG and neutralizing antibodies in post-COVID-19 patients. Infection, 2021, 50, 447.	2.3	5
119	Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants. Nature, 2021, 600, 530-535.	13.7	124
121	Challenges to Vaccination against SARS-CoV-2 in Patients with Immune-Mediated Diseases. Vaccines, 2021, 9, 1147.	2.1	8

#	Article	IF	Citations
122	Airway antibodies emerge according to COVID-19 severity and wane rapidly but reappear after SARS-CoV-2 vaccination. JCI Insight, 2021, 6, .	2.3	27
124	RNA Vaccines against Infectious Diseases: Vital Progress with Room for Improvement. Vaccines, 2021, 9, 1211.	2.1	5
126	Antibody-Mediated Rejection: the Role of Plasma Cells and Memory B Cells. Current Transplantation Reports, 2021, 8, 272-280.	0.9	0
128	The immunology of asymptomatic SARS-CoV-2 infection: what are the key questions?. Nature Reviews Immunology, 2021, 21, 762-768.	10.6	80
131	Robust SARS-CoV-2 Antibody Responses in Asian COVID-NaÃ¯ve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine. Vaccines, 2021, 9, 1241.	2.1	12
133	Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6Âmonths cross-sectional study. Journal of Neuroimmunology, 2021, 361, 577746.	1.1	63
134	What Happens to the Immune System after Vaccination or Recovery from COVID-19?. Life, 2021, 11, 1152.	1.1	5
135	Scientific rationale for developing potent RBD-based vaccines targeting COVID-19. Npj Vaccines, 2021, 6, 128.	2.9	102
137	COVID-19 in B Cell-Depleted Patients After Rituximab: A Diagnostic and Therapeutic Challenge. Frontiers in Immunology, 2021, 12, 763412.	2.2	43
138	BNT162b2 vaccination induces durable SARS-CoV-2â€“specific T cells with a stem cell memory phenotype. Science Immunology, 2021, 6, eabl5344.	5.6	166
139	Protective immunity after recovery from SARS-CoV-2 infection. Lancet Infectious Diseases, The, 2022, 22, 12-14.	4.6	114
140	Mechanisms underpinning poor antibody responses to vaccines in ageing. Immunology Letters, 2022, 241, 1-14.	1.1	28
141	Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2. Clinica Chimica Acta, 2022, 524, 11-17.	0.5	16
143	Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses â€” are we our own worst enemy?. Nature Reviews Immunology, 2022, 22, 47-56.	10.6	118
144	Impact of Distinct Therapies on Antibody Response to <scp>SARSâ€CoV</scp>â€2 Vaccine in Systemic Lupus Erythematosus. Arthritis Care and Research, 2022, 74, 562-571.	1.5	25
145	Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe, The, 2022, 3, e52-e61.	3.4	436
146	Anti-SARS-CoV-2 antibodies elicited by COVID-19 mRNA vaccine exhibit a unique glycosylation pattern. Cell Reports, 2021, 37, 110114.	2.9	44
147	Are COVID-19 Vaccine Boosters Needed? The Science behind Boosters. Journal of Virology, 2022, 96, JVI0197321.	1.5	35

#	Article	IF	Citations
148	Modelling the concentration of anti-SARS-CoV-2 immunoglobulin G in intravenous immunoglobulin product batches. PLoS ONE, 2021, 16, e0259731.	1.1	8
149	Long-Term Humoral Immune Response against SARS-CoV-2 after Natural Infection and Subsequent Vaccination According to WHO International Binding Antibody Units (BAU/mL). Viruses, 2021, 13, 2336.	1.5	10
150	m6A Regulator-Mediated Methylation Modification Patterns and Characteristics of Immunity in Blood Leukocytes of COVID-19 Patients. Frontiers in Immunology, 2021, 12, 774776.	2.2	17
151	A Single Dose of SARS-CoV-2 Vaccine Primes a Strong Humoral Immune Response in COVID-19â€“Recovered Patients. Viral Immunology, 2021, , .	0.6	6
152	Pre-existing immunity and vaccine history determine hemagglutinin-specific CD4 T cell and IgG response following seasonal influenza vaccination. Nature Communications, 2021, 12, 6720.	5.8	33
153	SARS-CoV-2 Spike-Specific T-Cell Responses in Patients With B-Cell Depletion Who Received Chimeric Antigen Receptor T-Cell Treatments. JAMA Oncology, 2022, 8, 164.	3.4	15
156	Antibody response to COVID-19 vaccine: A point of view that can help to optimize dose distribution. International Immunopharmacology, 2022, 102, 108406.	1.7	7
157	Humoral anti-SARS-CoV-2 immune response after two doses of Comirnaty vaccine in nursing home residents by previous infection status. Vaccine, 2022, 40, 531-535.	1.7	6
159	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. Cell, 2022, 185, 113-130.e15.	13.5	64
160	Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study. Lancet Rheumatology, The, 2022, 4, e113-e124.	2.2	24
161	Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses. Cell Host and Microbe, 2022, 30, 97-109.e5.	5.1	83
162	Neutralizing antibody: a savior in the Covid-19 disease. Molecular Biology Reports, 2022, 49, 2465-2474.	1.0	18
165	A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern. Cell Reports Medicine, 2022, 3, 100486.	3.3	16
166	Impact of prior SARS-CoV-2 infection on incidence of hospitalization and adverse events following mRNA SARS-CoV-2 vaccination: A nationwide, retrospective cohort study. Vaccine, 2022, 40, 1082-1089.	1.7	9
167	Persistent B cell memory after SARS-CoV-2 vaccination is functional during breakthrough infections. Cell Host and Microbe, 2022, 30, 400-408.e4.	5.1	75
168	Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants. Science, 2022, 375, 183-192.	6.0	91
169	SARS-CoV-2 BNT162b2 vaccineâ€“induced humoral response and reactogenicity in individuals with prior COVID-19 disease. JCI Insight, 2022, 7, .	2.3	5
171	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. Pharmacological Reviews, 2022, 74, 313-339.	7.1	9

#	Article	IF	Citations
172	SARS-CoV-2 Variants, Vaccines, and Host Immunity. Frontiers in Immunology, 2021, 12, 809244.	2.2	176
173	Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naÃ¯ve healthcare workers. EBioMedicine, 2022, 75, 103805.	2.7	60
174	Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19. Cell Reports, 2022, 38, 110235.	2.9	35
176	Population homogeneity for the antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age ranges. Nature Communications, 2022, 13, 140.	5.8	22
177	Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents. Nature Communications, 2022, 13, 153.	5.8	45
178	Viral Load in COVID-19 Patients: Implications for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants. Frontiers in Medicine, 2021, 8, 836826.	1.2	15
179	Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection. ELife, 2022, 11, .	2.8	19
180	Decreased memory B cell frequencies in COVIDâ€19 delta variant vaccine breakthrough infection. EMBO Molecular Medicine, 2022, 14, e15227.	3.3	31
181	SARS-CoV-2 in Kidney Transplant Recipients: A Systematic Review. Transplantology, 2022, 3, 33-48.	0.3	3
182	Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients. Med, 2022, 3, 104-118.e4.	2.2	38
184	Transcriptome Analysis of Peripheral Blood Mononuclear Cells in SARS-CoV-2 NaÃ¯ve and Recovered Individuals Vaccinated With Inactivated Vaccine. Frontiers in Cellular and Infection Microbiology, 2021, 11, 821828.	1.8	8
185	SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people. Cell Reports, 2022, 38, 110336.	2.9	41
186	Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals. Cell, 2022, 185, 1008-1024.e15.	13.5	101
187	Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine. Cell Discovery, 2022, 8, 10.	3.1	100
188	Immunity to SARS-CoV-2 up to 15Âmonths after infection. IScience, 2022, 25, 103743.	1.9	56
189	Distinct immune response to CoronaVac in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic disease. Lancet Rheumatology, The, 2022, 4, e77-e78.	2.2	2
190	Data structures associated with biomedical research. , 2022, , 19-43.		0
191	SARS-CoV-2 infection and vaccination trigger long-lived B and CD4+ T lymphocytes with implications for booster strategies. Journal of Clinical Investigation, 2022, 132, .	3.9	30

#	Article	IF	Citations
192	Vaccination of <scp>COVID</scp>â€19 convalescent plasma donors increases binding and neutralizing antibodies against <scp>SARSâ€CoV</scp>â€2 variants. Transfusion, 2022, 62, 563-569.	0.8	7
193	Antibody Response to SARS-CoV-2 Infection and Vaccination in COVID-19-naÃ¯ve and Experienced Individuals. Viruses, 2022, 14, 370.	1.5	5
194	Distinct Homologous and Variant-Specific Memory B-Cell and Antibody Response Over Time After Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccination. Journal of Infectious Diseases, 2022, 226, 23-31.	1.9	17
195	SARS-CoV-2 Omicron-neutralizing memory B cells are elicited by two doses of BNT162b2 mRNA vaccine. Science Immunology, 2022, 7, eabn8590.	5.6	88
196	Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2â€“experienced individuals. Science Translational Medicine, 2022, 14, .	5.8	65
197	HLAâ€dependent variation in SARSâ€CoVâ€2 CD8Â⁺ T cell crossâ€reactivity with human coronaviruses. Immunology, 2022, 166, 78-103.	2.0	16
198	Exercise after influenza or COVID-19 vaccination increases serum antibody without an increase in side effects. Brain, Behavior, and Immunity, 2022, 102, 1-10.	2.0	30
199	Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza. Npj Vaccines, 2021, 6, 153.	2.9	46
200	Antibody affinity maturation and cross-variant activity following SARS-CoV-2 mRNA vaccination: Impact of prior exposure and sex. EBioMedicine, 2021, 74, 103748.	2.7	17
201	Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infectious Diseases, The, 2022, 22, 483-495.	4.6	232
202	The germinal centre B cell response to SARS-CoV-2. Nature Reviews Immunology, 2022, 22, 7-18.	10.6	150
203	Neutralizing Antibody Response to Pseudotype Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Differs Between mRNA-1273 and BNT162b2 Coronavirus Disease 2019 (COVID-19) Vaccines and by History of SARS-CoV-2 Infection. Clinical Infectious Diseases, 2022, 75, e827-e837.	2.9	9
204	Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older Adults. Journal of Infectious Diseases, 2022, 225, 1129-1140.	1.9	65
206	Single-cell profiling of T and B cell repertoires following SARS-CoV-2 mRNA vaccine. JCI Insight, 2021, 6, .	2.3	54
207	Longitudinal dynamics of SARS-CoV-2-specific cellular and humoral immunity after natural infection or BNT162b2 vaccination. PLoS Pathogens, 2021, 17, e1010211.	2.1	37
208	Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant. Vaccines, 2021, 9, 1442.	2.1	18
209	Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants. Science, 2021, , eabm0811.	6.0	10
210	Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals. Science Translational Medicine, 2021, , eabi8961.	5.8	22

#	Article	IF	Citations
211	Severity of adverse reactions is associated with T-cell response in mRNA-1273 vaccinated health care workers. Clinical and Experimental Vaccine Research, 2022, 11, 121.	1.1	7
213	Comparative Magnitude and Persistence of Humoral SARS-CoV-2 Vaccination Responses in the Adult Population in Germany. Frontiers in Immunology, 2022, 13, 828053.	2.2	11
214	SARS-CoV-2 antibody and T cell responses one year after COVID-19 and the booster effect of vaccination: A prospective cohort study. Journal of Infection, 2022, 84, 171-178.	1.7	25
215	Vaccine Type-, Age- and Past Infection-Dependence of the Humoral Response to SARS-CoV-2 Spike S Protein. Frontiers in Immunology, 2022, 13, 809285.	2.2	7
216	SARS-CoV-2-Specific Antibody (Ab) Levels and the Kinetic of Ab Decline Determine Ab Persistence Over 1 Year. Frontiers in Medicine, 2022, 9, 822316.	1.2	2
218	Memory B Cells Induced by Sputnik V Vaccination Produce SARS-CoV-2 Neutralizing Antibodies Upon Ex Vivo Restimulation. Frontiers in Immunology, 2022, 13, 840707.	2.2	11
219	Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy. Npj Vaccines, 2022, 7, 28.	2.9	64
220	Comparative Immunogenicity of COVID-19 Vaccines in a Population-Based Cohort Study with SARS-CoV-2-Infected and Uninfected Participants. Vaccines, 2022, 10, 324.	2.1	9
222	Specific Anti-SARS-CoV-2 Humoral and Cellular Immune Responses After Booster Dose of BNT162b2 Pfizer-BioNTech mRNA-Based Vaccine: Integrated Study of Adaptive Immune System Components. Frontiers in Immunology, 2022, 13, 856657.	2.2	25
223	Deciphering the Neurosensory Olfactory Pathway and Associated Neo-Immunometabolic Vulnerabilities Implicated in COVID-Associated Mucormycosis (CAM) and COVID-19 in a Diabetes Backdropâ€"A Novel Perspective. International Journal of Diabetology, 2022, 3, 193-235.	0.9	6
224	The (apparent) antibody paradox in COVID-19. Expert Review of Clinical Immunology, 2022, 18, 335-345.	1.3	9
226	Short-Term Adverse Events and Antibody Response to the BNT162b2 SARS-CoV-2 Vaccine in 4156 Health Care Professionals. Vaccines, 2022, 10, 439.	2.1	7
227	Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination. Cell Reports Medicine, 2022, 3, 100603.	3.3	27
229	Adverse reactions and production of neutralizing anti-SARS-CoV-2 antibodies after ChAdOx1 COVID-19 vaccination: A cross-sectional study in a single center. Journal of Infection and Public Health, 2022, 15, 360-364.	1.9	1
230	Enhanced immunity after Ad26.COV2.S vaccine breakthrough infection. Cell Reports Medicine, 2022, 3, 100579.	3.3	1
231	Neutralizing Antibodies Responses against SARS-CoV-2 in a Sardinian Cohort Group Up to 9 Months after BNT162b2 Vaccination. Vaccines, 2022, 10, 531.	2.1	5
232	Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination. Journal of Infectious Diseases, 2022, 226, 1372-1381.	1.9	41
233	AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2. BMC Medicine, 2022, 20, 128.	2.3	17

#	Article	IF	Citations
234	Sex, Age, and Ethnic Background Shape Adaptive Immune Responses Induced by the SARS-CoV-2 mRNA Vaccine. Frontiers in Immunology, 2022, 13, 786586.	2.2	13
235	Population differences in antibody response to SARSâ€CoVâ€2 infection and BNT162b2 vaccination. FASEB Journal, 2022, 36, e22223.	0.2	7
236	Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals. MBio, 2022, 13, e0379821.	1.8	28
237	Why are children less affected than adults by severe acute respiratory syndrome coronavirus 2 infection?. , 2022, 19, 555-557.		7
238	HLAâ€DR polymorphism in SARSâ€CoVâ€2 infection and susceptibility to symptomatic COVIDâ€19. Immunology, 2022, 166, 68-77.	2.0	18
239	Vaccines Against COVID-19: A Review. Vaccines, 2022, 10, 414.	2.1	8
240	mRNA vaccination in octogenarians 15 and 20Âmonths after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron. Cell Reports, 2022, 39, 110680.	2.9	21
241	Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study. Lancet Rheumatology, The, 2022, 4, e338-e350.	2.2	88
242	Increased antibody response after SARS-CoV-2 mRNA-based vaccination in rituximab-treated patients with previous COVID-19 infection. Rheumatology, 2022, , .	0.9	1
243	A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern. Communications Medicine, 2022, 2, .	1.9	3
245	Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine. Cell, 2022, 185, 1875-1887.e8.	13.5	148
247	Seroconversion panels demonstrate anti-SARS-CoV-2 antibody development after administration of the mRNA-1273 vaccine. Vaccine, 2022, 40, 2993-2998.	1.7	1
248	Convergent CDR3 homology amongst Spike-specific antibody responses in convalescent COVID-19 subjects receiving the BNT162b2 vaccine. Clinical Immunology, 2022, 237, 108963.	1.4	4
249	Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naÃ¯ve and previously infected individuals. EBioMedicine, 2022, 78, 103972.	2.7	31
250	SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8+ T cells. Nature Immunology, 2022, 23, 781-790.	7.0	116
251	Hybrid immunity against COVID-19 in different countries with a special emphasis on the Indian scenario during the Omicron period. International Immunopharmacology, 2022, 108, 108766.	1.7	12
252	Clinical Considerations During Breakthrough Coronavirus Disease 2019 Infections in Vaccinated Individuals With Autoimmunity. Open Forum Infectious Diseases, 2021, 8, ofab577.	0.4	0
253	Assessment of Post-Vaccination Antibody Response Eight Months after the Administration of BNT1622b2 Vaccine to Healthcare Workers with Particular Emphasis on the Impact of Previous COVID-19 Infection. Vaccines, 2021, 9, 1508.	2.1	12

#	Article	IF	Citations
254	The benefit of boosters: diversity and inclusion in the COVIDâ€19 memory response. Immunology and Cell Biology, 2022, 100, 15-17.	1.0	2
255	Kinetics and persistence of antiâ€SARSâ€CoVâ€2 neutralisation and antibodies after BNT162b2 vaccination in a Swiss cohort. Immunity, Inflammation and Disease, 2022, 10, .	1.3	5
256	SARS-CoV-2 spike-specific memory B cells express higher levels of T-bet and FcRL5 after non-severe COVID-19 as compared to severe disease. PLoS ONE, 2021, 16, e0261656.	1.1	16
257	Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies. Blood Cancer Journal, 2021, 11, 202.	2.8	14
261	Elucidating T Cell and B Cell Responses to SARS-CoV-2 in Humans: Gaining Insights into Protective Immunity and Immunopathology. Cells, 2022, 11, 67.	1.8	7
262	Secretory IgA and TÂcells targeting SARS-CoV-2 spike protein are transferred to the breastmilk upon mRNA vaccination. Cell Reports Medicine, 2021, 2, 100468.	3.3	27
263	A Promising Vaccination Strategy against COVID-19 on the Horizon: Heterologous Immunization. Journal of Microbiology and Biotechnology, 2021, 31, 1601-1614.	0.9	8
264	Impact of SARSâ€CoVâ€2 infection on vaccineâ€induced immune responses over time. Clinical and Translational Immunology, 2022, 11, e1388.	1.7	20
267	Boosting maternal and neonatal humoral immunity following SARS-CoV-2 infection using a single messenger RNA vaccine dose. American Journal of Obstetrics and Gynecology, 2022, 227, 486.e1-486.e10.	0.7	7
268	Effectiveness of COVID-19 mRNA Vaccination in Preventing COVID-19â€“Associated Hospitalization Among Adults with Previous SARS-CoV-2 Infection â€" United States, June 2021â€“February 2022. Morbidity and Mortality Weekly Report, 2022, 71, 549-555.	9.0	72
271	Smart Mushroom-Inspired Imprintable and Lightly Detachable (MILD) Microneedle Patterns for Effective COVID-19 Vaccination and Decentralized Information Storage. ACS Nano, 2022, 16, 7512-7524.	7.3	19
272	Distinct immune cell dynamics correlate with the immunogenicity and reactogenicity of SARS-CoV-2 mRNA vaccine. Cell Reports Medicine, 2022, 3, 100631.	3.3	22
273	The Effect of Waning on Antibody Levels and Memory B Cell Recall following SARS-CoV-2 Infection or Vaccination. Vaccines, 2022, 10, 696.	2.1	11
274	Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?. Nature Reviews Immunology, 2022, 22, 387-397.	10.6	93
275	Transient production of receptor-binding domain of SARS-CoV-2 in Nicotiana benthamiana plants induces specific antibodies in immunized mice. Molecular Biology Reports, 2022, 49, 6113-6123.	1.0	3
276	Evaluation of Natural and Vaccine-Induced Anti-SARS-CoV-2 Immunity: A Comparative Study between Different Groups of Volunteers. Diseases (Basel, Switzerland), 2022, 10, 25.	1.0	4
277	Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines. Mucosal Immunology, 2022, 15, 584-594.	2.7	41
278	Broad humoral and cellular immunity elicited by one-dose mRNA vaccination 18 months after SARS-CoV-2 infection. BMC Medicine, 2022, 20, 181.	2.3	10

#	Article	IF	Citations
279	COVID-19 vaccination challenges: A mini-review. Human Vaccines and Immunotherapeutics, 2022, 18, 1-9.	1.4	5
280	Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial. Journal of Infectious Diseases, 2022, 226, 1731-1742.	1.9	8
281	Long-term serological SARS-CoV-2 IgG kinetics following mRNA COVID-19 vaccine: real-world data from a large cohort of healthcare workers. International Journal of Infectious Diseases, 2022, 122, 1-7.	1.5	6
282	COVID-19 vaccine development: milestones, lessons and prospects. Signal Transduction and Targeted Therapy, 2022, 7, 146.	7.1	153
283	Transcriptome and TCR Repertoire Measurements of CXCR3+ T Follicular Helper Cells Within HIV-Infected Human Lymph Nodes. Frontiers in Immunology, 2022, 13, .	2.2	1
284	Instructing durable humoral immunity for COVID-19 and other vaccinable diseases. Immunity, 2022, 55, 945-964.	6.6	32
285	Biological and Immune Responses to Current Anti-SARS-CoV-2 mRNA Vaccines beyond Anti-Spike Antibody Production. Journal of Immunology Research, 2022, 2022, 1-7.	0.9	4
286	Association between history of HBV vaccine response and anti-SARS-CoV-2 spike antibody response to the BioNTech/Pfizerâ€™s BNT162b2 mRNA SARS-CoV-2 vaccine among healthcare workers in Japan: A prospective observational study. PLoS ONE, 2022, 17, e0268529.	1.1	2
287	Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study. PLoS Medicine, 2022, 19, e1003991.	3.9	75
288	ASSESSMENT OF THE HUMORAL IMMUNITY INDUCED BY SPUTNIK V COVID-19 VACCINE (GAM-COVID-VAC) IN HEALTHCARE WORKERS. Vacunas (English Edition), 2022, , .	0.3	0
289	Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in NaÃ¯ve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals. Frontiers in Immunology, 2022, 13, .	2.2	11
290	Heterogeneous SARS-CoV-2 humoral response after COVID-19 vaccination and/or infection in the general population. Scientific Reports, 2022, 12, .	1.6	8
291	B cell-derived cfDNA after primary BNT162b2 mRNA vaccination anticipates memory B cells and SARS-CoV-2 neutralizing antibodies. Med, 2022, 3, 468-480.e5.	2.2	2
292	Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses. Nature Immunology, 2022, 23, 960-970.	7.0	39
293	Third trimester messenger RNA COVID-19 booster vaccination upsurge maternal and neonatal SARS-CoV-2 immunoglobulin G antibody levels at birth. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2022, 274, 148-154.	0.5	7
294	An Update on Protective Effectiveness of Immune Responses After Recovery From COVID-19. Frontiers in Immunology, 0, 13, .	2.2	7
296	Antibody Response Induced by BNT162b2 and mRNA-1273 Vaccines against the SARS-CoV-2 in a Cohort of Healthcare Workers. Viruses, 2022, 14, 1235.	1.5	5
297	The past, current and future epidemiological dynamic of SARS-CoV-2. Oxford Open Immunology, 2022, 3, .	1.2	24

#	Article	IF	Citations
298	Antibody Binding and Angiotensin-Converting Enzyme 2 Binding Inhibition Is Significantly Reduced for Both the BA.1 and BA.2 Omicron Variants. Clinical Infectious Diseases, 2023, 76, e240-e249.	2.9	11
299	Boosting corrects a memory B cell defect in SARS-CoV-2 mRNAâ€“vaccinated patients with inflammatory bowel disease. JCI Insight, 2022, 7, .	2.3	5
300	Neutralising reactivity against SARS-CoV-2 Delta and Omicron variants by vaccination and infection history. Genome Medicine, 2022, 14, .	3.6	15
301	Statistics of antibody binding to the spike protein explain the dependence of COVID 19 infection risk on antibody concentration and affinity. Scientific Reports, 2022, 12, .	1.6	4
303	Immunological memory to <scp>SARSâ€CoV</scp>â€2 infection and <scp>COVID</scp>â€19 vaccines. Immunological Reviews, 2022, 310, 27-46.	2.8	137
304	Functional Profiling of In Vitro Reactivated Memory B Cells Following Natural SARS-CoV-2 Infection and Gam-COVID-Vac Vaccination. Cells, 2022, 11, 1991.	1.8	5
306	Comparison of COVID-19 Vaccines Introduced in Korea. Biomedical Science Letters, 2022, 28, 67-82.	0.0	1
307	Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	59
308	Activation of Anti-SARS-CoV-2 Human CTLs by Extracellular Vesicles Engineered with the N Viral Protein. Vaccines, 2022, 10, 1060.	2.1	4
309	Early human B cell signatures of the primary antibody response to mRNA vaccination. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	17
311	The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. Frontiers in Immunology, 0, 13, .	2.2	28
312	Evaluation of lymphocyte count, T-cell subsets and neutrophil-to-lymphocyte ratio as early predictors for severity and outcome of COVID-19 diseaseâ€“a report from a highly complex hospital in Brazil. Hematology, Transfusion and Cell Therapy, 2022, , .	0.1	3
313	Tissue immunity to SARSâ€CoVâ€2: Role in protection and immunopathology*. Immunological Reviews, 2022, 309, 25-39.	2.8	11
314	Immunogenicity and efficacy of Ad26.<scp>COV2</scp>.S: An adenoviral vectorâ€“based <scp>COVID</scp>â€19 vaccine. Immunological Reviews, 2022, 310, 47-60.	2.8	10
315	Duration of COVID-19 mRNA Vaccine Effectiveness against Severe Disease. Vaccines, 2022, 10, 1036.	2.1	2
317	Immune Cells Profiles In The Peripheral Blood Of Patients With Moderate To Severe COVID-19 And Healthy Subjects With and Without Vaccination With The Pfizer-BioNTech mRNA Vaccine. Frontiers in Immunology, 0, 13, .	2.2	4
318	Immune responses to Sinopharm/<scp>BBIBPâ€CorV</scp> in individuals in Sri Lanka. Immunology, 2022, 167, 275-285.	2.0	8
319	Impact of Prior Infection on SARS-CoV-2 Antibody Responses in Vaccinated Long-Term Care Facility Staff. MSphere, 2022, 7, .	1.3	3

#	Article	IF	Citations
320	The kinetics of IgG subclasses and contributions to neutralizing activity against SARSâ€CoVâ€2 wildâ€type strain and variants in healthy adults immunized with inactivated vaccine. Immunology, 2022, 167, 221-232.	2.0	10
322	Persistent Maintenance of Intermediate Memory B Cells Following SARS-CoV-2 Infection and Vaccination Recall Response. Journal of Virology, 2022, 96, .	1.5	11
323	<scp>COVID</scp>â€19 and plasma cells: Is there longâ€lived protection?*. Immunological Reviews, 2022, 309, 40-63.	2.8	26
324	SARS-CoV-2 Reinfection Rate and Outcomes in Saudi Arabia: A National Retrospective Study. International Journal of Infectious Diseases, 2022, 122, 758-766.	1.5	15
325	Immune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adults. Nature Communications, 2022, 13, .	5.8	43
327	The deciphering of the immune cells and marker signature in COVIDâ€19 pathogenesis: An update. Journal of Medical Virology, 2022, 94, 5128-5148.	2.5	12
328	A Complementary Union of SARS-CoV2 Natural and Vaccine Induced Immune Responses. Frontiers in Immunology, 0, 13, .	2.2	8
329	Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination. International Journal of Infectious Diseases, 2022, 122, 793-801.	1.5	17
330	SARS-CoV-2-Specific Memory B Cell Responses Are Maintained After Recovery from Natural Infection and Postvaccination. Viral Immunology, 0, , .	0.6	5
331	Modelling the interplay of SARS-CoV-2 variants in the United Kingdom. Scientific Reports, 2022, 12, .	1.6	11
332	Seroprevalence Surgery of Anti-SARS-CoV-2 Antibodies Based on COVID-19 Vaccine Type in Academy Community, East Kalimantan, Indonesia. Open Access Macedonian Journal of Medical Sciences, 2022, 10, 1169-1173.	0.1	0
334	Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses. Frontiers in Immunology, 0, 13, .	2.2	21
335	A Rapid and Sensitive Microfluidics-Based Tool for Seroprevalence Immunity Assessment of COVID-19 and Vaccination-Induced Humoral Antibody Response at the Point of Care. Biosensors, 2022, 12, 621.	2.3	7
336	High baseline expression of IL-6 and IL-10 decreased CCR7 B cells in individuals with previous SARS-CoV-2 infection during BNT162b2 vaccination. Frontiers in Immunology, 0, 13, .	2.2	0
339	Robust humoral and cellular immune responses in long-term convalescent COVID-19 individuals following one-dose SARS-CoV-2 inactivated vaccination. Frontiers in Immunology, 0, 13, .	2.2	2
340	Immunogenicity of SARS-CoV-2 vaccines in patients with cancer. Trends in Molecular Medicine, 2022, 28, 1082-1099.	3.5	11
341	Gut microbiota-derived metabolites confer protection against SARS-CoV-2 infection. Gut Microbes, 2022, 14, .	4.3	26
342	<scp>COVID</scp>â€19 vaccine humoral response in frequent platelet donors with plateletpheresisâ€associated lymphopenia. Transfusion, 2022, 62, 1779-1790.	0.8	4

#	Article	IF	Citations
343	COVID-19: Pathophysiology, Transmission, and Drug Development for Therapeutic Treatment and Vaccination Strategies. Current Pharmaceutical Design, 2022, 28, 2211-2233.	0.9	1
344	Strong T-cell activation in response to COVID-19 vaccination in multiple sclerosis patients receiving B-cell depleting therapies. Frontiers in Immunology, 0, 13, .	2.2	14
345	Differences in B-Cell Immunophenotypes and Neutralizing Antibodies Against SARS-CoV-2 After Administration of BNT162b2 (Pfizer-BioNTech) Vaccine in Individuals with and without Prior COVID-19 - A Prospective Cohort Study. Journal of Inflammation Research, 0, Volume 15, 4449-4466.	1.6	3
350	Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose. Nature Communications, 2022, 13, .	5.8	27
351	Antibody response after first and second BNT162b2 vaccination to predict the need for subsequent injections in nursing home residents. Scientific Reports, 2022, 12, .	1.6	2
352	Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity. MBio, 2022, 13, .	1.8	18
353	Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?. Biomedicine and Pharmacotherapy, 2022, 154, 113522.	2.5	56
354	Factors influencing neutralizing antibody titers elicited by coronavirus disease 2019 vaccines. Microbes and Infection, 2023, 25, 105044.	1.0	7
355	What are the prospects for durable immune control?. Infectious Diseases Now, 2022, , .	0.7	0
356	Updated Results of the COVID-19 in MS Global Data Sharing Initiative. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	26
357	Protective Immunity of COVID-19 Vaccination with ChAdOx1 nCoV-19 Following Previous SARS-CoV-2 Infection: A Humoral and Cellular Investigation. Viruses, 2022, 14, 1916.	1.5	7
359	The role of B cells in COVID-19 infection and vaccination. Frontiers in Immunology, 0, 13, .	2.2	25
361	Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial. Nature Communications, 2022, 13, .	5.8	18
362	New insights into human immune memory from <scp>SARSâ€CoV</scp> â€2 infection and vaccination. Allergy: European Journal of Allergy and Clinical Immunology, 0, , .	2.7	5
363	Lymphocyte Subpopulations Associated with Neutralizing Antibody Levels of SARS-CoV-2 for COVID-19 Vaccination. Vaccines, 2022, 10, 1550.	2.1	4
364	Evidence of premature lymphocyte aging in people with low anti-spike antibody levels after BNT162b2 vaccination. IScience, 2022, 25, 105209.	1.9	2
365	Cross-direct effects in settings with two mediators. Biostatistics, 0, , .	0.9	0
366	Effects of Prior Infection with SARS-CoV-2 on B Cell Receptor Repertoire Response during Vaccination. Vaccines, 2022, 10, 1477.	2.1	2

#	Article	IF	Citations
367	Seroprevalence of SARS-CoV-2 infection in the Tyrolean district of Schwaz at the time of the rapid mass vaccination in March 2021 following B.1.351-variant outbreak. Frontiers in Public Health, 0, 10, .	1.3	3
368	Associations of Immunogenicity and Reactogenicity After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine in the COVE and TeenCOVE Trials. Clinical Infectious Diseases, 2023, 76, 271-280.	2.9	3
369	The need for more holistic immune profiling in next-generation SARS-CoV-2 vaccine trials. Frontiers in Immunology, 0, 13, .	2.2	1
370	Asymptomatic or symptomatic SARS-CoV-2 infection plus vaccination confers increased adaptive immunity to variants of concern. IScience, 2022, 25, 105202.	1.9	3
371	SARSâ€CoVâ€2 infection and multi-organ system damage: a review. Bosnian Journal of Basic Medical Sciences, 0, , .	0.6	17
374	How Do Anti-SARS-CoV-2 mRNA Vaccines Protect from Severe Disease?. International Journal of Molecular Sciences, 2022, 23, 10374.	1.8	10
377	Dynamics of B-Cell Responses after SARS-CoV-2 Vaccination in Spain. Vaccines, 2022, 10, 1615.	2.1	2
380	SARS-CoV-2 in immunocompromised individuals. Immunity, 2022, 55, 1779-1798.	6.6	50
381	Humoral and Cellular Immune Responses After a 3-dose Course of mRNA-1273 COVID-19 Vaccine in Kidney Transplant Recipients: A Prospective Cohort Study. Transplantation Direct, 2022, 8, e1389.	0.8	4
382	Humoral and cellular immune response over 9Âmonths of mRNA-1273, BNT162b2 and ChAdOx1 vaccination in a University Hospital in Spain. Scientific Reports, 2022, 12, .	1.6	9
383	Enhanced immune responses following heterologous vaccination with self-amplifying RNA and mRNA COVID-19 vaccines. PLoS Pathogens, 2022, 18, e1010885.	2.1	10
384	The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern. PLoS Pathogens, 2022, 18, e1010882.	2.1	8
385	A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses. Cell Reports, 2022, 41, 111554.	2.9	14
388	SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared with SARS-CoV-2 mRNA vaccinations. Cell Reports, 2022, 41, 111496.	2.9	20
389	A combined fine needle aspiration and spectral flow cytometry approach to assess human germinal center responses to SARS-CoV-2 vaccination. STAR Protocols, 2022, 3, 101840.	0.5	3
390	SARS-CoV-2â€"The Role of Natural Immunity: A Narrative Review. Journal of Clinical Medicine, 2022, 11, 6272.	1.0	12
391	Healthcare Worker Study Cohort to Determine the Level and Durability of Cellular and Humoral Immune Responses after Two Doses of SARS-CoV-2 Vaccination. Vaccines, 2022, 10, 1784.	2.1	1
392	Assessing T-Cell Immunity in Kidney Transplant Recipients with Absent Antibody Production after a 3rd Dose of the mRNA-1273 Vaccine. International Journal of Molecular Sciences, 2022, 23, 12333.	1.8	4

#	Article	IF	Citations
393	210-Day Kinetics of Total, IgG, and Neutralizing Spike Antibodies across a Course of 3 Doses of BNT162b2 mRNA Vaccine. Vaccines, 2022, 10, 1703.	2.1	5
395	Infant Antibody Repertoires during the First Two Years of Influenza Vaccination. MBio, 2022, 13, .	1.8	3
396	Adverse Events Following Immunization With mRNA and Viral Vector Vaccines in Individuals With Previous Severe Acute Respiratory Syndrome Coronavirus 2 Infection From the Canadian National Vaccine Safety Network. Clinical Infectious Diseases, 2023, 76, 1088-1102.	2.9	6
397	Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection. PLoS ONE, 2022, 17, e0276241.	1.1	5
398	HIV skews the SARS-CoV-2 B cell response towards an extrafollicular maturation pathway. ELife, 0, 11, .	2.8	6
399	Longitudinal Analyses after COVID-19 Recovery or Prolonged Infection Reveal Unique Immunological Signatures after Repeated Vaccinations. Vaccines, 2022, 10, 1815.	2.1	0
400	Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine. Frontiers in Immunology, 0, 13, .	2.2	4
402	The lymphatic system and COVID-19 vaccines. Frontiers in Immunology, 0, 13, .	2.2	3
403	Mucosal and Systemic Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Determined by Severity of Primary Infection. MSphere, 2022, 7, .	1.3	3
405	A systematic and thematic analysis of the top 100 cited articles on mRNA vaccine indexed in Scopus database. Human Vaccines and Immunotherapeutics, 0, , .	1.4	2
406	Comparison of three different COVID-19 vaccine platforms (CoronaVac, BTN162b2, and Ad5-nCoV) in individuals with and without prior COVID-19: Reactogenicity and neutralizing antibodies. Immunology Letters, 2022, 251-252, 20-28.	1.1	5
407	Neutralizing antibodies and T-cell responses to inactivated SARS-CoV-2 vaccine in COVID-19 convalescents one and a half years after infection. Virus Research, 2023, 323, 198977.	1.1	0
408	Landscape of infection enhancing antibodies in COVID-19 and healthy donors. Computational and Structural Biotechnology Journal, 2022, 20, 6033-6040.	1.9	5
409	mRNA vaccines for COVID-19. , 2023, , 611-624.		0
410	Flow cytometric protocol to characterize human memory B cells directed against SARS-CoV-2 spike protein antigens. STAR Protocols, 2022, 3, 101902.	0.5	3
411	A Rare Case of BIA-ALCL Mass Associated with Mastectomy Skin Flap Erythema After Immunization with COVID-19. Aesthetic Plastic Surgery, 2023, 47, 116-121.	0.5	1
412	Quantifying Antibody Persistence After a Single Dose of <scp>COVID</scp>â€19 Vaccine Ad26.<scp>COV2</scp>.S in Humans Using a Mechanistic Modeling and Simulation Approach. Clinical Pharmacology and Therapeutics, 2023, 113, 380-389.	2.3	3
413	Highâ€“temporal resolution profiling reveals distinct immune trajectories following the first and second doses of COVID-19 mRNA vaccines. Science Advances, 2022, 8, .	4.7	7

#	Article	IF	Citations
415	Anti-Ad26 humoral immunity does not compromise SARS-COV-2 neutralizing antibody responses following Gam-COVID-Vac booster vaccination. Npj Vaccines, 2022, 7, .	2.9	5
416	Dynamics of humoral immune response in SARS-CoV-2 infected individuals with different clinical stages. Frontiers in Immunology, 0, 13, .	2.2	0
417	Seroepidemiological and genomic investigation of SARS-CoV-2 spread in North East region of India. Indian Journal of Medical Microbiology, 2022, , .	0.3	0
418	Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities. Npj Vaccines, 2022, 7, .	2.9	10
419	Kinetics of Humoral Immunity against SARS-CoV-2 in Healthcare Workers after the Third Dose of BNT162b2 mRNA Vaccine. Vaccines, 2022, 10, 1948.	2.1	3
420	Strong neutralizing antibody responses to SARS-CoV-2 variants following a single vaccine dose in subjects with previous SARS-CoV-2 infection. Open Forum Infectious Diseases, 0, , .	0.4	4
421	Maturation of SARS-CoV-2 Spike-specific memory B cells drives resilience to viral escape. IScience, 2023, 26, 105726.	1.9	9
422	Assessing the long-stand antibody response induced by COVID-19 vaccines: A study in an educational cohort in San Luis, Argentina. Vaccine, 2022, , .	1.7	0
423	Profiling the B cell immune response elicited by vaccination against the respiratory virus SARS-CoV-2. Frontiers in Immunology, 0, 13, .	2.2	6
424	Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination. Biochemical Society Transactions, 2022, 50, 1643-1658.	1.6	6
425	The BNT162b2 vaccine induces humoral and cellular immune memory to SARS-CoV-2 Wuhan strain and the Omicron variant in children 5 to 11 years of age. Frontiers in Immunology, 0, 13, .	2.2	9
426	B-Cell Responses to Sars-Cov-2 mRNA Vaccines. Pathogens and Immunity, 2022, 7, 93-119.	1.4	0
427	Donor selection for adoptive cell therapy with CD45RAâ^' memory T cells for patients with coronavirus disease 2019, and dexamethasone and interleukin-15 effects on the phenotype, proliferation and interferon gamma release. Cytotherapy, 2023, 25, 330-340.	0.3	2
428	Vaccination induces HIV broadly neutralizing antibody precursors in humans. Science, 2022, 378, .	6.0	71
429	Variations within the Glycan Shield of SARS-CoV-2 Impact Viral Spike Dynamics. Journal of Molecular Biology, 2023, 435, 167928.	2.0	24
430	Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice. Scientific Reports, 2022, 12, .	1.6	2
431	BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants. Nature Communications, 2022, 13, .	5.8	42
432	Long-term durability of immune responses to the BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex. Scientific Reports, 2022, 12, .	1.6	20

#	Article	IF	Citations
433	SARS-CoV-2 booster vaccination rescues attenuated IgG1 memory B cell response in primary antibody deficiency patients. Frontiers in Immunology, 0, 13, .	2.2	1
435	Analysis of Antigenâ€Specific T and B Cells for Monitoring Immune Protection Against SARSâ€CoVâ€2. Current Protocols, 2023, 3, .	1.3	4
436	Spike recognition and neutralization of SARS-CoV-2 Omicron subvariants elicited after the third dose of mRNA vaccine. Cell Reports, 2023, 42, 111998.	2.9	15
437	Epsteinâ€“Barr Virusâ€Positive Hemophagocytic Lymphohistiocytosis Following COVIDâ€19 Vaccination in a Pediatric Patient. Pediatric Blood and Cancer, 2023, 70, .	0.8	0
438	Humoral immunity for durable control of SARS-CoV-2 and its variants. Inflammation and Regeneration, 2023, 43, .	1.5	6
439	Updated Insights into the T Cell-Mediated Immune Response against SARS-CoV-2: A Step towards Efficient and Reliable Vaccines. Vaccines, 2023, 11, 101.	2.1	14
440	Durable immune responses after BNT162b2 vaccination in home-dwelling old adults. Vaccine: X, 2023, 13, 100262.	0.9	9
441	Impacts of viral pathogenesis and vaccine immunization on the host humoral immune response in SARS-CoV-2 and associated variants of concern (VOCs) infection. , 2023, , 237-262.		0
442	Risk of Repeated Adverse Effects following Booster Dose of mRNA COVID-19 Vaccine: Results from the MOSAICO Study. Vaccines, 2023, 11, 247.	2.1	7
443	Longitudinal monitoring of mRNA-vaccine-induced immunity against SARS-CoV-2. Frontiers in Immunology, 0, 14, .	2.2	5
444	Cohort profile: A QuÃ©bec-based plasma donor biobank to study COVID-19 immunity (PlasCoV). BMJ Open, 2023, 13, e068803.	0.8	4
445	THE ESTIMATION OF NATURAL AND VACCINE-INDUCED IMMUNITY FOR PROTECTION OF NEW CORONAVIRUS INFECTION IN PERSONS WHO HAVE CONTACT WITH COVID-19. CLINICAL OBSERVATIONS. LaboratornaÃ¢ I KliniÄeskaÃ¢ Medicina FarmaciÃ¢, 2022, , 4-16.	0.1	1
446	Defending against SARS-CoV-2: The T cell perspective. Frontiers in Immunology, 0, 14, .	2.2	20
448	A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4+ TÂcell profile. Cell Reports Medicine, 2023, 4, 100955.	3.3	1
449	Pre-existing immunity modulates responses to mRNA boosters. Cell Reports, 2023, 42, 112167.	2.9	12
450	Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease. Immunity, 2023, 56, 669-686.e7.	6.6	43
451	Humoral immune response to SARS-CoV-2 mRNA vaccines is associated with choice of vaccine and systemic adverse reactions DMD TNR. Clinical and Experimental Vaccine Research, 2023, 12, 60.	1.1	0
453	Single-cell RNA-seq analysis identifies distinct myeloid cells in a case with encephalitis temporally associated with COVID-19 vaccination. Frontiers in Immunology, 0, 14, .	2.2	0

#	Article	IF	Citations
454	Impact of Previous Common Human Coronavirus Exposure on SARS-CoV-2-Specific T-Cell and Memory B-Cell Response after mRNA-Based Vaccination. Viruses, 2023, 15, 627.	1.5	2
456	Hyperacute optic neuritis in a patient with COVID-19 infection and vaccination: a case report. BMC Ophthalmology, 2023, 23, .	0.6	1
457	Immune response to BNT162b2 SARS-CoV-2 vaccine in patients living with HIV: The COVIH-DAPT study. Frontiers in Immunology, 0, 14, .	2.2	2
458	Long-term adaptive response in COVID-19 vaccine recipients and the effect of a booster dose. Frontiers in Immunology, 0, 14, .	2.2	5
459	Short- and long-term T cell and antibody responses following dexamethasone treatment in COVID-19. JCI Insight, 2023, 8, .	2.3	1
460	Influence of age, gender, previous SARS-CoV-2 infection, and pre-existing diseases in antibody response after COVID-19 vaccination: A review. Molecular Immunology, 2023, 156, 148-155.	1.0	13
461	Longer intervals between SARSâ€CoVâ€2 infection and mRNAâ€1273 doses improve the neutralization of different variants of concern. Journal of Medical Virology, 2023, 95, .	2.5	1
462	CIDP: Analysis of Immunomarkers During COVID-19 mRNA-Vaccination and IVIg-Immunomodulation: An Exploratory Study. Journal of NeuroImmune Pharmacology, 0, , .	2.1	0
464	Tracking B Cell Memory to SARS-CoV-2 Using Rare Cell Analysis System. Vaccines, 2023, 11, 735.	2.1	0
465	Salivary Antibody Responses to Two COVID-19 Vaccines following Different Vaccination Regimens. Vaccines, 2023, 11, 744.	2.1	1
467	Pre-clinical models to define correlates of protection for SARS-CoV-2. Frontiers in Immunology, 0, 14, .	2.2	3
468	Humoral and cellular immunity in three different types of COVID-19 vaccines against SARS-CoV-2 variants in a real-world data analysis. Journal of Microbiology, Immunology and Infection, 2023, 56, 705-717.	1.5	6
469	Immune correlates of protection for SARS-CoV-2, Ebola and Nipah virus infection. Frontiers in Immunology, 0, 14, .	2.2	7
470	Antibody and memory B cell responses to the dengue virus <scp>NS1</scp> antigen in individuals with varying severity of past infection. Immunology, 0, , .	2.0	0
471	Immunodominant SARSâ€CoVâ€2â€specific CD4⁺ and CD8⁺ Tâ€cell responses elicited by inactivated vaccines in healthy adults. Journal of Medical Virology, 2023, 95, .	2.5	3
472	Vaccination of SARS-CoV-2-infected individuals expands a broad range of clonally diverse affinity-matured B cell lineages. Nature Communications, 2023, 14, .	5.8	1
473	Bioinspired peptides induce different cell death mechanisms against opportunistic yeasts. Probiotics and Antimicrobial Proteins, 0, , .	1.9	0
474	Timing and implications for immune response to vaccine in SARS-CoV-2 breakthrough infections. IScience, 2023, 26, 106716.	1.9	1

#	Article	IF	Citations
495	Knifeâ€™s edge: Balancing immunogenicity and reactogenicity in mRNA vaccines. Experimental and Molecular Medicine, 2023, 55, 1305-1313.	3.2	11
519	B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity. , 2024, 21, 144-158.		4
534	Targets of SARS-CoV-2: therapeutic implications for COVID-19. , 2024, , 3-14.		0
536	Activation-based repertoire analysis for T cell clonal dynamics in hybrid COVID-19 immunity. Nature Immunology, 2024, 25, 7-8.	7.0	0